Skip to content
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
Read more about the article Health Canada Continues to Support Psychedelic Medicine

Health Canada Continues to Support Psychedelic Medicine

  • Post author:Olly PP
  • Post published:May 24, 2022
  • Post category:News

Continue ReadingHealth Canada Continues to Support Psychedelic Medicine
Read more about the article Burnaby company granted Health Canada licence to produce ‘magic mushroom medicine’

Burnaby company granted Health Canada licence to produce ‘magic mushroom medicine’

  • Post author:Olly PP
  • Post published:May 20, 2022
  • Post category:News

Continue ReadingBurnaby company granted Health Canada licence to produce ‘magic mushroom medicine’
Read more about the article The Mission to Make Psilocybin Available to UK Cancer Patients

The Mission to Make Psilocybin Available to UK Cancer Patients

  • Post author:Olly PP
  • Post published:April 25, 2022
  • Post category:News

Continue ReadingThe Mission to Make Psilocybin Available to UK Cancer Patients
Read more about the article Is the UK Becoming a Global Center for Psychedelic Medicine?

Is the UK Becoming a Global Center for Psychedelic Medicine?

  • Post author:Olly PP
  • Post published:March 15, 2022
  • Post category:News

Continue ReadingIs the UK Becoming a Global Center for Psychedelic Medicine?
Read more about the article Using Real-World Evidence to Accelerate Psychedelic Drug Development

Using Real-World Evidence to Accelerate Psychedelic Drug Development

  • Post author:Olly PP
  • Post published:February 9, 2022
  • Post category:News
  • Post comments:0 Comments

Continue ReadingUsing Real-World Evidence to Accelerate Psychedelic Drug Development
Read more about the article Albert Labs receives conditional approval for CSE listing

Albert Labs receives conditional approval for CSE listing

  • Post author:Olly PP
  • Post published:November 30, 2021
  • Post category:News
  • Post comments:0 Comments

Continue ReadingAlbert Labs receives conditional approval for CSE listing
Read more about the article Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker

Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker

  • Post author:Olly PP
  • Post published:November 29, 2021
  • Post category:News
  • Post comments:0 Comments

Continue ReadingAnother Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
Read more about the article ViewPoints Interview: Albert Labs’ Dr. Malcolm Barratt-Johnson Shares Insights on Psychedelic-Assisted Therapies

ViewPoints Interview: Albert Labs’ Dr. Malcolm Barratt-Johnson Shares Insights on Psychedelic-Assisted Therapies

  • Post author:barneyneal96
  • Post published:June 19, 2021
  • Post category:News
  • Post comments:0 Comments

Continue ReadingViewPoints Interview: Albert Labs’ Dr. Malcolm Barratt-Johnson Shares Insights on Psychedelic-Assisted Therapies
Read more about the article Drug developer uses RWE to research psychedelic therapies

Drug developer uses RWE to research psychedelic therapies

  • Post author:barneyneal96
  • Post published:June 19, 2021
  • Post category:News
  • Post comments:0 Comments

Continue ReadingDrug developer uses RWE to research psychedelic therapies
Read more about the article Albert Labs announces C$4M financing ahead of CSE listing

Albert Labs announces C$4M financing ahead of CSE listing

  • Post author:Olly PP
  • Post published:April 15, 2021
  • Post category:News
  • Post comments:0 Comments

Continue ReadingAlbert Labs announces C$4M financing ahead of CSE listing

Recent Posts

  • Albert Labs Announces Private Placement
  • Letter of Intent (LOI) for First-In-Human studies with iNGENÅ« CRO
  • Albert Labs Provides Corporate Update
  • Psychedelic Therapy isn’t Fringe Anymore
  • Can Psychedelics Cure?

Recent Comments

    Innovative mental health medicines for patients with unmet needs

    • Legal Disclaimer
    • Privacy Policy
    • Modern Slavery Statement
    • Cookie Policy
    Menu
    • Legal Disclaimer
    • Privacy Policy
    • Modern Slavery Statement
    • Cookie Policy

    © 2022 Albert Labs. All Rights Reserved

    • About
    • Team
    • Clinical Trials
    • KRN-101
    • Investing
    • Press & Updates
    • Contact
    Menu
    • About
    • Team
    • Clinical Trials
    • KRN-101
    • Investing
    • Press & Updates
    • Contact
    Twitter Linkedin Youtube Envelope
    CSE:ABRT
    FSE: VB50
    CSE:ABRT
    FSE: VB50

    About Albert Labs

    We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

    If you would like support or more information around making an investment, please contact investing@albertlabs.com

    Twitter Linkedin Youtube Envelope

    Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

    Latest Press Release

    Albert Labs Announces Private Placement

    Read more
    Twitter
    Youtube
    Linkedin
    Instagram
    Envelope

    Latest Press Release

    Albert Labs Announces Private Placement

    Read more

    By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.